In a report released yesterday, Balaji Prasad from Barclays maintained a Hold rating on Phibro Animal Health (PAHC), with a price target of $24.00. The company’s shares closed last Monday at $17.79, close to its 52-week low of $16.87.
According to TipRanks.com, Prasad ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -15.4% and a 19.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Dr Reddy’s Laboratories, and Bausch Health Companies.
The word on The Street in general, suggests a Hold analyst consensus rating for Phibro Animal Health with a $24.33 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.98 and a one-year low of $16.87. Currently, Phibro Animal Health has an average volume of 163.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Phibro Animal Health Corp. engages in the manufacture of animal health and mineral nutrition products. It operates through the following business segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops, manufactures, and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment comprises of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment offers production of specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.